Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) -- CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...

Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...